Argent BioPharma (RGT) Competitors GBX 16.75 0.00 (0.00%) (As of 09/18/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitors RGT vs. CEL, PXS, CHLL, MXC, N4P, HELD, HLN, HIK, HCM, and INDVShould you be buying Argent BioPharma stock or one of its competitors? The main competitors of Argent BioPharma include Celadon Pharmaceuticals (CEL), Provexis (PXS), Chill Brands Group (CHLL), Argent BioPharma (MXC), N4 Pharma (N4P), Hellenic Dynamics (HELD), Haleon (HLN), Hikma Pharmaceuticals (HIK), HUTCHMED (HCM), and Indivior (INDV). These companies are all part of the "drug manufacturers - specialty & generic" industry. Argent BioPharma vs. Celadon Pharmaceuticals Provexis Chill Brands Group Argent BioPharma N4 Pharma Hellenic Dynamics Haleon Hikma Pharmaceuticals HUTCHMED Indivior Argent BioPharma (LON:RGT) and Celadon Pharmaceuticals (LON:CEL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation, community ranking and institutional ownership. Does the media favor RGT or CEL? In the previous week, Celadon Pharmaceuticals had 1 more articles in the media than Argent BioPharma. MarketBeat recorded 1 mentions for Celadon Pharmaceuticals and 0 mentions for Argent BioPharma. Celadon Pharmaceuticals' average media sentiment score of 0.08 beat Argent BioPharma's score of 0.00 indicating that Celadon Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Argent BioPharma Neutral Celadon Pharmaceuticals Neutral Which has more risk and volatility, RGT or CEL? Argent BioPharma has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Comparatively, Celadon Pharmaceuticals has a beta of -0.25, indicating that its share price is 125% less volatile than the S&P 500. Is RGT or CEL more profitable? Argent BioPharma's return on equity of 0.00% beat Celadon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Argent BioPharmaN/A N/A -108.57% Celadon Pharmaceuticals N/A -142.14%-34.58% Does the MarketBeat Community prefer RGT or CEL? Celadon Pharmaceuticals received 4 more outperform votes than Argent BioPharma when rated by MarketBeat users. CompanyUnderperformOutperformArgent BioPharmaN/AN/ACeladon PharmaceuticalsOutperform Votes4100.00% Underperform VotesNo Votes Do analysts prefer RGT or CEL? Celadon Pharmaceuticals has a consensus target price of GBX 235, suggesting a potential upside of 552.78%. Given Celadon Pharmaceuticals' higher possible upside, analysts clearly believe Celadon Pharmaceuticals is more favorable than Argent BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Argent BioPharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/ACeladon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders hold more shares of RGT or CEL? 1.1% of Argent BioPharma shares are owned by institutional investors. Comparatively, 11.2% of Celadon Pharmaceuticals shares are owned by institutional investors. 7.4% of Argent BioPharma shares are owned by insiders. Comparatively, 67.6% of Celadon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has preferable earnings and valuation, RGT or CEL? Celadon Pharmaceuticals has higher revenue and earnings than Argent BioPharma. Celadon Pharmaceuticals is trading at a lower price-to-earnings ratio than Argent BioPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArgent BioPharmaN/AN/A-£17.53M-£0.24-69.42Celadon Pharmaceuticals£11.26K2,117.53-£7.14M-£0.12-300.00 SummaryCeladon Pharmaceuticals beats Argent BioPharma on 11 of the 14 factors compared between the two stocks. Ad True Gold RepublicChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a population of over 1.4 BILLION is “buying gold like there’s no tomorrow,” according to The New York Times. China, a rising global economic threat, aims to reduce its dependence on the US dollar… . Click here now to get your free 'De-Dollarization' Guide. Get Argent BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for RGT and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat are MarkeBeat Followers?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RGT vs. The Competition Export to ExcelMetricArgent BioPharmaDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£8.07M£1.21B£5.64B£1.40BDividend YieldN/A3.19%4.34%11.74%P/E Ratio-69.42191.33145.221,616.70Price / SalesN/A4,102.601,636.74182,071.26Price / CashN/A10.1236.8432.63Price / Book-1.513.094.842.83Net Income-£17.53M£148.09M£114.76M£152.86M7 Day Performance10.15%0.86%4.18%2.94%1 Month PerformanceN/A0.40%9.46%-1.71%1 Year PerformanceN/A241.28%28.89%29.72% Argent BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CELCeladon Pharmaceuticals1.986 of 5 stars1.99 / 5 starsGBX 36.48-4.0%GBX 235+544.2%-74.3%£24.16M£11,258.00-304.002,780Gap DownHigh Trading VolumePXSProvexis0 of 5 stars0.00 / 5 starsGBX 0.62-4.9%N/A-7.7%£14.04M£426,168.0043.754News CoverageGap DownCHLLChill Brands Group0 of 5 stars0.00 / 5 starsGBX 2.15flatN/AN/A£10.89M£624,187.00-215.007MXCArgent BioPharma0 of 5 stars0.00 / 5 starsGBX 22+4.8%N/A+19,900.0%£9.65M£1.32M-13.255Gap UpN4PN4 Pharma0 of 5 stars0.00 / 5 starsGBX 0.52-0.4%N/A-57.7%£2.07M£23,524.00-52.305Gap DownHELDHellenic Dynamics0 of 5 stars0.00 / 5 starsGBX 0.95flatN/AN/A£1.40MN/A0.00N/ANews CoverageHLNHaleon0.2827 of 5 stars0.28 / 5 starsGBX 392.30+1.3%GBX 367.50-6.3%+20.5%£35.74B£11.26B3,269.1725,408HIKHikma Pharmaceuticals1.7674 of 5 stars1.77 / 5 starsGBX 1,927-0.2%GBX 2,325+20.7%-7.2%£4.28B£3.02B2,964.629,100News CoverageHCMHUTCHMED0 of 5 stars0.00 / 5 starsGBX 261+1.8%N/A-1.2%£2.23B£610.81M-6,525.001,760Gap UpINDVIndivior2.9958 of 5 stars3.00 / 5 starsGBX 744+2.4%GBX 1,500+101.6%-59.8%£974.86M£1.15B-930.001,000 Related Companies and Tools Related Companies: Celadon Pharmaceuticals Alternatives Provexis Alternatives Chill Brands Group Alternatives Argent BioPharma Alternatives N4 Pharma Alternatives Hellenic Dynamics Alternatives Haleon Alternatives Hikma Pharmaceuticals Alternatives HUTCHMED Alternatives Indivior Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:RGT) was last updated on 9/18/2024 by MarketBeat.com Staff From Our Partners44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored625,000% GainThe recent crypto correction has shaken many investors, causing panic and uncertainty. But while others are fr...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Argent BioPharma Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Argent BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
